News

One of the earliest researchers to explore therapeutic applications of implanted brain-computer interfaces, Phil Kennedy, founder of Neural Signals, Inc., announced that his firm has entered into a joint-venture relationship to market a BCI system. The new firm, called Neural Logistics LLC, is joint venture between Neural Signals and a public firm called DarkPulse, Inc. Neural Logistics is seeking…

Among all the neurological and neuromuscular diseases and disorders, cerebral palsy represents a significant untapped potential for neurotech vendors. Although the Bioness L300 system received FDA clearance for treating foot-drop in children with CP in 2013, there have been few neurotech approaches to treat the underlying cause. CP is the most common of all childhood disabilities, with about 500,000 children and more than 250,000 adults in the U.S.

Apple Inc. has long been interested in developing wellness capabilities for their wearable devices, such as ECG and glucose monitoring in Apple Watch and EEG sensing for detection of cognitive states (based on EEG activity in the alpha frequency band) in AirPods. More recently, Apple’s interests started to expand toward developing medical devices for bioelectronic medicine disorders. One of their r…

It’s fashionable these days for business leaders to decry the role of government in their industry, and to be sure, there are many in the neurotechnology industry who could point to seemingly senseless regulatory decisions and policies that have been harmful to growth. But there can be no denying that the U.S. neurotechnology industry has also been the recipient of government largess over the years, when you consider the amount of funding that has been available from agencies such as the NIH, DARPA, and the VA.

In recent months, an number of firms in the neurorehabilitation space have offered new therapies helping stroke patients recover. But while there has been significant activity in the neurovascular space, there have been few neuromodulation approaches to treating the cerebrovascular causes of stroke. About 20 years ago, a California firm called PhotoThera sought to market a laser stimulation system that delivered pulses of near-infrared laser energy through the skull to selected portions of the brain.

Neurotech Reports, the publisher of this newsletter, announced that the fourth annual Neurotech Commercialization Workshop will take place on July 27, 2023. The one-day event will take place on-line using the Zoom platform. The workshop will feature tutorial and interactive sessions with Neurotech Reports editors James Cavuoto, Jeremy Koff, and Jo Jo Platt. The morning agenda, free to advanced regi…

In the evolving landscape of medical advancements, an emerging field of interest is the use of ultrasound technology for therapeutic neuromodulation. The application of ultrasound to modulate the function of peripheral nerve pathways is called peripheral focused ultrasound stimulation and is becoming a potential tool in the management of chronic diseases. A recent study by a team at GE Research, di…

The National Institutes of Health held the 9th Annual BRAIN Initiative Meeting in Bethesda, MD earlier this month. The hybrid meeting was the first to welcome in-person attendance since before the pandemic. Eager researchers and enthusiasts alike grabbed the limited number of spots for in person attendance causing the organizers to put people on a waiting list while they arranged for additional space at the meeting site.

Long-time readers of this publication will recall that we have frequently approached the subjects of ethics in neurotechnology and protecting users’ privacy. Particularly in this space, we have long advocated for “neuro vigilance” against potential threats posed -computer interfaces and deep-brain stimulation. And as NBR senior contributing editor JoJo Platt points out in her coverage of the recent…

Glioblastoma, the deadly brain cancer that impacts about 12,000 people in the U.S. each year, remains one of the most significant unmet medical needs facing the healthcare industry. The five-year survival rate is under 10% and patients survive an average of 15 to 18 months after diagnosis. Recently, several emerging bioelectronic medicine firms and research teams have reported progress at developing therapies for glioblastoma, though there is still a long road ahead for these efforts.